The significance of chirality in drug design and development

Current Topics in Medicinal Chemistry

Volumn 11, Issue 7, 2011, Pages 760-770

  Brooks, W H ^a   Guida, W C ^a,b   Daniel, K G ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Chiral; Computational chemistry; Drug design; Drug discovery; Enantiomer; FDA guidelines; In silico; Virtual screening

Indexed keywords

ARTICLE; CHIRALITY; DIASTEREOISOMER; DRUG DESIGN; DRUG DEVELOPMENT; ENANTIOMER; FOOD AND DRUG ADMINISTRATION; STEREOCHEMISTRY;

DRUG DESIGN; GUIDELINES AS TOPIC; HUMANS; LIBRARIES, DIGITAL; MODELS, CHEMICAL; STEREOISOMERISM; UNITED STATES;

EID: 79953662872     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802611795165098     Document Type: Article

References (36)

1. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I. N.; Bourne, P.E. The protein data bank. Nucleic Acids Res., 2000, 28, 1, 235-242.
2. Grant, M. A. Protein structure prediction in structure-based ligand design and virtual screening. Comb. Chem. High Throughput Screen., 2009, 12(10), 940-960.
3. Administration, F.D. Development of new stereoisomeric drugs. 2005 July 6, 2005 [cited 2010 April 23]; www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122883.htm.
4. Nic, M.; Jirat, J.; Kosata, B. IUPAC Gold Book Compendium of chemical terminology. 2005 [cited 2010 April 26]; http://goldbook.iupac.org
5. Caldwell, J.; Wainer, I.W. Stereochemistry: definitions and a note on nomenclature. Hum. Psychopharmacol., 2001, 16(S2), S105-S107.
6. Sahajwalla, C. In: Regulatory Considerations in Drug Development of Stereoisomers., Chirality in Drug Design and Development, Reddy, I.; Mehvar, R.; Eds. 2004, CRC Press: New York.
7. Lee, E.J.; Williams, K.; Day, R.; Graham, G.; Champion, D. Stereoselective disposition of ibuprofen enantiomers in man. Br. J. Clin. Pharmacol., 1985, 19(5), 669-674.
8. Hardikar, M. Chiral non-steroidal anti-inflammatory drugs - a review. J. Indian Med. Assoc., 2008, 106, 615-624.
9. Rouhi, A. Chirality at work. Chem. Engin. News, 2003, 81, 56-61.
10. Agranat, I.; Caner, H.; Caldwell, J. Putting chirality to work: the strategy of chiral switches. Nat. Rev. Drug Discov., 2002, 1(10), 753-768.
11. Gupta, H.; Kumar, S.; Roy, S.; Gaud, R.S. Patent protection strategies. J. Pharm. BioAllied Sci., 2010, 2(1), 2-7.
12. Faget, K. Why FDCA Section 505(u) Should not concern us greatly. Mich. Telecomm. Tech. L. Rev., 2009, 453-466.
13. Yoshitani, R.; Cooper, E. Pharmaceutical reformulation: the growth of life cycle management. Houston J. Health Law Policy, 2007, 7, 379-410.
14. Agency, E. M. Investigation of chiral active substances. 1994 [cited 2010 April 25]; www.ema.europa.eu/pdfs/human/qwp/3cc29aeu.pdf
15. Health Canada. Therapeutic Products Programme, Health Canada, 2007.
16. Harmonization, I.C.o. Specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances, Q6A, Step 4. 1999 [cited 2010 April 25]; www.ich.org/cache/compo/363-272-1.html#Q6A
17. Caner, H.; Groner, E.; Levy, L. Trends in the development of chiral drugs. Drug Discov. Today, 2004, 9, 105-110.
18. AMA. Geometric isomerism and chirality: the USAN perspective. 1995 [cited 2010 April 25]; www.ama-assn.org/ama/pub/about-ama/our-people/coalitions-consortiums/united-states-adopted-names-council/name-guidelines/geometric-isomerism-chirality-the-usan-perspective.shtml.
19. Stinson, S. Chiral drugs. Chem Eng News, 2000, 78, 55-78.
20. Mentel, M.; Blankenfeldt, W.; Breinbauer, R. The active site of an enzyme can host both enantiomers of a racemic ligand simultaneously. Angew Chem. Int. Ed. Engl., 2009, 48, 9084-9087.
21. Fokkens, J.; Klebe, G. A simple protocol to estimate differences in protein binding affinity for enantiomers without prior resolution of racemates. Angew. Chem. Int. Ed. Engl., 2006, 45(6), 985-989.
22. Aller, S.G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P.M.; Trinh, Y.T.; Zhang, Q.; Urbatsch, I.L.; Chang, G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science, 2009, 323(5922), 1718-1722.
23. Ghosh, S.; Nie, A.; An, J.; Huang, Z. Structure-based virtual screening of chemical libraries for drug discovery. Curr. Opin. Chem. Biol., 2006, 10(3), 194-202.
24. Schrodinger, Schrodinger Software Suite, Schrodinger LLC: New York, 2006.
25. Morris, G.M.; Huey, R.; Lindstrom, W.; Sanner, M.F.; Belew, R.K.; Goodsell, D.S.; Olson, A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem., 2009, 30(16), 2785-2791.
26. Verdonk, M.L.; Chessari, G.; Cole, J.C.; Hartshorn, M.J.; Murray, C.W.; Nissink, J.W.; Taylor, R.D.; Taylor, R. Modeling water molecules in protein-ligand docking using GOLD. J. Med. Chem., 2005, 48(20), 6504-6515.
27. Brooks, W.H.; McCloskey, D.E.; Daniel, K.G.; Ealick, S.E.; Secrist J.A.; Waud, W.R.; Pegg, A.E.; Guida, W.C. In silico chemical library screening and experimental validation of a novel 9-aminoacridine based lead-inhibitor of human S-adenosylmethionine decarboxylase. J. Chem. Inf. Model, 2007, 47(5), 1897-1905.
28. Sadowski, J.; Gasteiger, J.; Klebe, G. Comparison of automatic three-dimensional model builders using 639 x-ray structures. H. Chem Inf. Comput. Sci., 1994, 34(4), 1000-1008.
29. Pearlman, R. Rapid generation of high quality approximate 3-dimensional molecular structures. Chem. Des. Auto News, 1987, 2.(1) 5-6.
30. Dalby, A.; Nourse, J.G.; Hounshell, W.D.; Gushurst, A.K.I.; Grier, D.L.; Leland, B.A.; Laufer, J. Description of several chemical structure file formats used by computer programs developed at molecular design limited. J. Chem. Inf. Comput. Sci., 1992, 32, 244-255.
31. Brooks, W.H.; Daniel, K.G.; Sung, S.S.; Guida, W.C. Computational validation of the importance of absolute stereochemistry in virtual screening. J. Chem. Inf. Model., 2008, 48(3), 639-645.
32. Biggadike, K.; Bledsoe, R.K.; Hassell, A.M.; Kirk, B.E.; McLay, I.M.; Shewchuk, L.M.; Stewart, E.L. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain. J. Med. Chem., 2008, 51(12), 3349-3352.
33. Vassilev, L.T.; Vu, B.T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 2004, 303, (5659), 844-848.
34. Istvan, E.S.; Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science, 2001, 292(5519), 1160-1164.
35. Zhou, Z.; Zhen, J.; Karpowich, N.K.; Law, C.J.; Reith, M.E.; Wang, D.N. Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nat. Struct. Mol. Biol., 2009, 16(6), 652-657.
36. Shoichet, B.K. DUD - A Directory of Useful Decoys. April 20th, 2010]; http://dud.docking.org/